申请人:ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD.
公开号:US20210292334A1
公开(公告)日:2021-09-23
The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyperfunctioning, such as certain types cancers. Compounds of formula (1) and methods of preparing the compounds are disclosed in the invention.